评估贝达基林的安全性:从不良事件报告系统分析的洞察力
Jiaqiang Wu1, Hong Pan2, Li Shen3
1School of Life Sciences and Biopharmaceutical Science, Shenyang Pharmaceutical University, Shenyang, China.
Frontiers in pharmacology
|May 24, 2024
概括
使用FAERS数据评估了贝达基林 (BDQ) 的安全性,揭示了耳部疾病等新的不良事件,并确定了肝损伤中的PI3K-Akt通路. 这突出了BDQQ的重点.
科学领域:
- 药物监督和药物安全研究
- 结核病治疗和药物开发
- 计算生物学和网络药理学
背景情况:
- 贝达基林 (BDQ) 是对多耐药结核病 (MDR-TB) 的关键进展.
- 贝达奎林 (BDQ) 的现实安全数据需要进一步的全面调查.
- 对于Bedaquiline (BDQ) 的特定不良事件 (AE) 和潜在机制的了解有限.
研究的目的:
- 通过使用不良事件 (AE) 数据,评估贝达基林 (BDQ) 的现实安全性.
- 识别和量化可能的贝达基林 (BDQ) 相关的不良事件 (AE).
- 为了阐明贝达基林 (BDQ) 诱导的肝损伤背后的分子机制.
主要方法:
- 从美国FDA FAERS数据库 (2012-2023) 收集和标准化Bedaquiline (BDQ) 的不良事件 (AE) 数据.
- 使用不成比例分析 (ROR,PRR,MGPS,BCPNN) 来检测AE信号.
- 利用后勤回归用于肝毒性分析和网络药理学来预测肝损伤机制.
主要成果:
- 识别了2017年Bedaquiline (BDQ) 相关病例报告,其中包括27个系统器官类 (SOC) 的341个优先术语 (PT).
- 发现了新的不良事件 (AE),包括以前没有记录的耳朵和迷宫障碍.
- 网络药理学确定PI3K-Akt信号通路是Bedaquiline (BDQ) 诱导的肝损伤的核心,在女性中具有保护性关联.
结论:
- 使用FAERS数据的贝达基林 (BDQ) 安全性分析揭示了以前未经记录的副作用和阐明的肝损伤机制.
- 网络药理学确定了贝达基林 (BDQ) 诱导的肝损伤中的PI3K-Akt通路,这表明了潜在的治疗点.
- 这些发现强调了持续对贝达基林 (BDQ) 药监的重要性,以确保安全有效的MDR-TB管理.
相关概念视频
Pharmacovigilance
825
Post-marketing surveillance is a critical component of pharmaceutical regulation, often uncovering unanticipated adverse drug reactions (ADRs) once a drug is widely used over an extended period.
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
This process, termed pharmacovigilance, aims to detect, evaluate, and minimize harmful effects related to medication use. The data collection for pharmacovigilance depends on spontaneous reporting systems, where healthcare professionals or patients voluntarily report suspected ADRs.
In some cases, there...
825
Drug Regulation
1.4K
Drug regulation encompasses the management of drug usage by evaluating its safety and efficacy through assessments conducted by regulatory authorities. Regrettably, the history of drug regulation is marred by several catastrophic events. One such incident is the Elixir Sulfanilamide tragedy, in which the toxic compound diethyl glycol was included in a sweet-tasting medication, leading to numerous fatalities. This event prompted the enactment of the Food, Drug, and Cosmetic Act in 1938. Under...
1.4K
Structure-Activity Relationships and Drug Design
699
Drug design is a dynamic field that involves discovering and developing new medications based on specific biological targets. This process heavily relies on structure-activity relationships (SAR) and quantitative structure-activity relationships (QSAR) to guide the design and optimization of efficient drugs.
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
SAR studies the intricate relationship between a drug's chemical structure and biological activity. It focuses on understanding how modifications to a drug's structure can influence...
699
Types of Biopharmaceutical Studies: Controlled and Non-Controlled Approaches
125
Biopharmaceutical studies constitute a vital field aiming to enhance drug delivery methods and refine therapeutic approaches, drawing upon diverse interdisciplinary knowledge. In research methodologies, the choice between controlled and non-controlled studies significantly influences the study's reliability and accuracy.
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
Non-controlled studies, commonly employed for initial exploration, lack a control group, rendering them susceptible to biases and external influences. In contrast,...
125
Antiepileptic Drugs: Potassium Channel Activators
173
Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Ezogabine has gained approval as an adjunctive treatment...
173


